Brief: Aardvark Therapeutics Plans To Unblind Hero And Ole Data To Inform Path Forward Following FDA Clinical Hold
14/05/2026 21:18
May 14 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS PLANS TO UNBLIND HERO AND OLE DATA TO INFORM PATH FORWARD FOLLOWING FDA CLINICAL HOLD AARDVARK THERAPEUTICS INC - FDA PLACES FULL CLINICAL HOLD ON AARDVARK'S IND FOR ARD-101 AARDVARK THERAPEUTICS INC - CLINICAL HOLD APPLIES TO ALL ONGOING PHASE 3 HERO AND OLE TRIALS FOR ARD-101 AARDVARK THERAPEUTICS INC - TO UNBLIND HERO AND OLE TRIAL DATA FOR ARD-101 FOR ASSESSMENT, DETERMINE NEXT STEPS FOR THE ARD-101 PROGRAM Source text: ID:nGNXJdz8k Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))